Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death

@article{Menger2012CardiacGE,
  title={Cardiac Glycosides Exert Anticancer Effects by Inducing Immunogenic Cell Death},
  author={Laurie Menger and Erika Vacchelli and Sandy Adjemian and Isabelle Martins and Yuting Ma and Shensi Shen and Takahiro Yamazaki and Abdul Qader Sukkurwala and Mick{\"a}el Michaud and Gregoire Mignot and Fr{\'e}d{\'e}ric Schlemmer and Eric Sulpice and Clara Locher and Xavier Gidrol and François Ghiringhelli and Nazanine Modjtahedi and Lorenzo Galluzzi and Fabrice Andr{\'e} and Laurence Zitvogel and Oliver Kepp and Guido Kroemer},
  journal={Science Translational Medicine},
  year={2012},
  volume={4},
  pages={143ra99 - 143ra99}
}
Cardiac glycosides kill cancer cells in a way that stimulates the immune response. A Cancer Double Feature—3807 A traditional chemotherapeutic drug performs a one-act play: It enters and kills a dividing cancer cell and then takes its bow. However, some chemotherapeutics have a wider range—they not only kill individual cancer cells but also do so in such a way that the dead cells function as a vaccine that primes the immune system to attack other cancer cells. Menger et al. now identify cardiac… 

The anticancer peptide RT53 induces immunogenic cell death

RT53 treatment induces all the hallmarks of immunogenic cell death, as defined by the plasma membrane exposure of calreticulin, release of ATP and the exodus of high-mobility group box 1 protein from dying cancer cells, through a non-regulated, membranolytic mode of action.

Natural compound inducers of immunogenic cell death

The potential role of metronomic immune modulation as well as targeted delivery of ICD-inducing compounds with nanoparticles or liposomal formulations to improving the immunogenicity of I CD inducers aiming at long-term clinical benefits are highlighted.

Natural compound inducers of immunogenic cell death

The potential role of metronomic immune modulation as well as targeted delivery of ICD-inducing compounds with nanoparticles or liposomal formulations to improving the immunogenicity of I CD inducers aiming at long-term clinical benefits are highlighted.

Anticancer metal drugs and immunogenic cell death.

Recombinant Lactaptin Induces Immunogenic Cell Death and Creates an Antitumor Vaccination Effect in Vivo with Enhancement by an IDO Inhibitor

It is demonstrated that recombinant human milk peptide lactaptin (RL2) induces death of cancer cells with ICD hallmarks in vitro with the release of ATP and high-mobility group box 1 protein (HMGB1) and exposure of calreticulin and HSP70 on the external cell membrane.

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

Recent developments on anticancer chemotherapy based on ICD inducers are discussed, including the case of cardiac glycosides, like digoxin and digitoxin, and zoledronic acid.

Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments

A brief outline of the well-characterized DAMPs such as calreticulin exposure, high-mobility group protein B1 (HMGB1), and adenosine triphosphate (ATP) release, which are induced by the morphologically distinct types of cell death are provided.

Hemidesmus indicus induces immunogenic death in human colorectal cancer cells

It is shown that Hemidesmus treatment induces tumor cell cytotoxicity characterized by surface expression of calreticulin, increased HSP70 expression and release of ATP and HMGB1, and suggests its potential relevance in innovative cancer immunotherapy protocols.

Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future.

This Tutorial Review will allow the readers to assess the progress in this fast-evolving field thus setting the stage for future advances.

Immunogenic Cell Death in Cancer Therapy

The mechanism of the "vaccination effect" of dying cancer cells undergoing ICD has been fully described, including the activation of specific antitumor response after re-challenge by the same living tumor cells.
...

References

SHOWING 1-10 OF 39 REFERENCES

Calreticulin exposure dictates the immunogenicity of cancer cell death

It is shown that anthracyclin-induced CRT translocation induces the rapid, preapoptotic translocation of calreticulin (CRT) to the cell surface and is identified as a key feature determining anticancer immune responses.

Cardiac Glycosides Induce Cell Death in Human Cells by Inhibiting General Protein Synthesis

The finding that cardiac glycosides inhibit protein synthesis provides a mechanism for the cytotoxicity of CGs and raises concerns about ongoing clinical trials to test CGs as anti-cancer agents in humans.

Classification of chemotherapeutic agents based on their differential in vitro effects on dendritic cells.

A DC biosensor clone developed by engineering the stable murine DC line XS106 to express the yellow fluorescent protein (YFP) gene under the control of interleukin (IL)-1beta promoter is used to screen 54 anticancer drugs.

Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death

It is shown that even in the absence of any adjuvant, tumor cells dying in response to anthracyclins can elicit an effective antitumor immune response that suppresses the growth of inoculated tumors or leads to the regression of established neoplasia.

Immunogenic death of colon cancer cells treated with oxaliplatin

OXP induces immunogenic death of CRC cells, and this effect determines its therapeutic efficacy in CRC patients, and both oxaliplatin and cisplatin were equally efficient in triggering HMGB1 release.

Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice

It is demonstrated that autophagy, which is often disabled in cancer, is dispensable for chemotherapy-induced cell death but required for its immunogenicity, and increased extracellular ATP concentrations improve the efficacy of antineoplastic chemotherapies when Autophagy is disabled.

Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

A previously unrecognized pathway for the activation of tumor antigen–specific T-cell immunity that involves secretion of the high-mobility-group box 1 (HMGB1) alarmin protein by dying tumor cells and the action of HMGB1 on Toll-like receptor 4 (TLR4) expressed by dendritic cells (DCs) is described.

Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.

The uptake of human myeloma cells by dendritic cells after tumor cell death by bortezomib leads to the induction of antitumor immunity, including against primary tumor cells, without the need for any additional adjuvants.

Cardiac glycosides as novel cancer therapeutic agents.

This review focuses on recent findings on cellular pharmacology of cardiac glycosides as they relate to treatment of human cancer and attempts to explain why these agents have been overlooked in the past.

Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress

The combination of ER stress inducers (such as THAPS or tunicamycin) and CDDP effectively induced the translocation of CRT to the plasma membrane, as well as immunogenic cell death, although ER stress or CDDP alone was insufficient to induce CRT exposure and immunogeniccell death.